Trial Profile
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Pegzilarginase (Primary)
- Indications Malignant melanoma; Small cell lung cancer; Solid tumours; Uveal melanoma
- Focus Adverse reactions; First in man
- Sponsors Aeglea Biotherapeutics; Spyre Therapeutics
- 27 Nov 2023 According to Spyre Therapeutics media release, Aeglea Biotherapeutics has changed its name to Spyre Therapeutics
- 13 Jun 2019 Status changed from recruiting to completed.
- 20 Dec 2018 Planned End Date changed from 1 Sep 2018 to 1 Jun 2019.